Replies to post #29225 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 1Q24 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  45%       +14% 
 Diagnostics       22%       -16%† 
 Nutrition         21%        +8% 
 Pharmaceuticals‡  12%       +14%

61% of overall corporate sales were ex-US.

*Includes diabetes care.
‡Branded generics and biosimilars in emerging markets.

†Excluding COVID diagnostics, 1Q24 diagnostics sales were +5% YoY. 1Q24 COVID-diagnostics sales were $204M (9% of total 1Q24 diagnostic sales) vs $730M in 1Q23.